Tests krill oil supplements in people with dry age-related macular degeneration
Tests krill oil capsules against a placebo in adults with dry macular degeneration.
Plain-language title generated from the registry record
Registry title: Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT05465252, who can take part
Where in China
- Shanghai General Hospital, Shanghai Jiao Tong UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT05465252
- Record updated
- 2 January 2026
- Original description
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.Read full original descriptionShow less
Effect of Krill Oil Supplementation on Dry Age-Related Macular Degeneration: A Randomized Controlled Trial
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.
Inclusion: Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (>125 μm), with or without AMD-related pigmentary abnormalities; Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin; Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months.
Exclusion: Long-term use of any medications that are associated with retinal or neural toxicities; History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment; Received cataract surgery in 3 months; Any eye with disease that would interfere with the fundus examinations; Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer; Other conditions not suitable for the current study; Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia; Surgeries that may interfere with AMD evaluation; Intraocular pressure more than 26 mmHg.